Overview

Gender

male

William Ringo has served as a member of our board of directors since October 2014. Since June 2010, William Ringo has served as a senior advisor to Barclays Healthcare Group. From April 2008 until his retirement in April 2010, William Ringo was Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc., a public pharmaceutical company, and was responsible for guiding Pfizer’s overall strategic planning and business development activities.

Prior to joining Pfizer, William Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, William Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc. Prior to Abgenix, William Ringo served for 28 years at Eli Lilly and Company in numerous executive roles, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. Following William Ringo retirement from Eli Lilly in 2001, from March 2001 to December 2007, William Ringo served on various boards of directors, including InterMune, Inc. where he served as the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003.

William Ringo currently serves on the boards of directors of Assembly Biosciences, Inc., Dermira, Inc., Immune Design Corp., Mirati Therapeutics, Inc., and Sangamo BioSciences, Inc., each of which is a public biotechnology company. William Ringo also served on the board of directors of Onyx Pharmaceuticals, Inc. from February 2011 until its acquisition by Amgen in October 2013. William Ringo received a B.S. in business administration and an M.B.A. from the University of Dayton.